ArticleInternational urology and nephrology2023
The significance of galactose-deficient immunoglobulin A1 staining in kidney diseases with IgA deposition.
Article in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinicopathological characteristics and renal outcomes of IgA nephropathy in systemic lupus erythematosus: a case report and systematic literature review.BMC nephrology · 2026Pooled it
- Clinical characteristics and prognosis of IgA nephropathy and comorbid diabetic kidney disease.Annals of medicine · 2026Article
- Kappa-Restricted IgA Nephropathy Treated Successfully With Targeted-Release Budesonide.Kidney international reports · 2026Article
- Immune mechanism of IgA vasculitis with nephritis: a narrative review.Frontiers in immunology · 2026Review
- Significance of KM55 immunohistochemical staining in the diagnosis and prognosis of IgA nephropathy.Journal of pathology and translational medicine · 2026Article
- Glomerular Galactose-Deficient IgA1 Deposition in 192 Autopsy Cases in Japan.Nephrology (Carlton, Vic.) · 2025Article
- Crohn's disease-associated IgA nephropathy may prone to better renal outcome.International urology and nephrology · 2024Article
- Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study investigated the significance of galactose-deficient immunoglobulin A1 staining in kidney diseases with IgA deposition.
methodsA total of 120 patients with IgA-dominant deposition in kidney tissues were enrolled and divided into four groups: primary IgA nephropathy (PIgAN), secondary IgA nephropathy (SIgAN), monotypic IgA nephropathy (MIgAN), and IgA variant monoclonal gammopathy of renal significance (IgA-MGRS). KM55 (the antibody of galactose-deficient immunoglobulin A1), IgA subtypes, and complement pathway factors (properdin, C4d, and C1q) were detected through immunofluorescence or immunohistochemistry analysis.
resultsKM55 and IgA double staining showed colocalization within glomeruli in all cases except for IgA-MGRS, which showed negative or weak staining of KM55 but strong staining of IgA. The PIgAN group showed the highest intensity of KM55 and KM55/IgA ratio, while these values in the IgA-MGRS group were the lowest (P < 0.01). A KM55/IgA quantified ratio of 0.78 was the optimal cut-off value to distinguish PIgAN from SIgAN, whereas a cut-off value of 0.21 was optimal to distinguish between MIgAN and IgA-MGRS. The clinicopathological characteristics showed significant differences as the groups were divided by diseases with optimal cut-off values, and these differences corresponded to the pathogenesis of each disease entity.
conclusionsPIgAN, SIgAN, and MIgAN are caused by the deposition of abnormally glycosylated IgA1 whereas IgA-MGRS is not. The KM55/IgA quantified ratio is valuable in distinguishing PIgAN from SIgAN, as well as MIgAN from IgA-MGRS.
Indexed as
Identifiers
36849627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.